Kyowa Kirin Acquires Orchard Therapeutics

Kriya Therapeutics Acquires Warden Bio

January 7, 2022

Biotechnology

Kriya Therapeutics acquired Warden Bio, obtaining exclusive rights to five preclinical AAV-mediated gene therapy programs targeting glycogen storage disorders and establishing a new Rare Disease Division. Warden Bio co‑founder Kunal Kishnani joins Kriya as President of the Rare Disease Division and Duke researchers associated with the programs will serve as scientific advisors.

Clinisys Acquires Orchard Software

July 29, 2025

Software

Clinisys has acquired Orchard Software from Francisco Partners, combining two leaders in laboratory informatics to expand Clinisys's LIS and LIMS capabilities. The deal brings Orchard's physician office, reference, and veterinary laboratory solutions into Clinisys's global cloud-based platform to broaden product capabilities and end-market coverage.

Merck KGaA Acquires SpringWorks Therapeutics for $3.4B

July 1, 2025

Pharmaceuticals

Merck KGaA, Darmstadt, Germany completed the acquisition of SpringWorks Therapeutics, Inc. for an enterprise value of $3.4 billion (US$47 per share in cash), following regulatory clearances and customary closing conditions. The deal adds SpringWorks' rare tumor portfolio — including OGSIVEO (nirogacestat) and GOMEKLI (mirdametinib) — to Merck's Healthcare business and is expected to be accretive to earnings by 2027 while strengthening Merck's rare tumor capabilities.

Bayer Acquires UK Biotech KaNDy Therapeutics Ltd.

August 11, 2020

Biotechnology

Bayer has agreed to acquire UK-based clinical-stage biotech KaNDy Therapeutics Ltd. for an upfront $425 million with up to $450 million in additional milestone payments, expanding Bayer's women's healthcare drug development pipeline—specifically the investigational non-hormonal compound NT-814 for menopausal vasomotor symptoms. The acquisition, subject to customary conditions, was announced in August 2020 and is expected to close in September 2020.

Francisco Partners Acquires Orchard Software Corporation

September 30, 2019

Software

Francisco Partners, a technology-focused private equity firm, announced it will acquire Orchard Software Corporation, a developer of laboratory information systems (LIS) used by clinical, pathology and outreach laboratories. The deal will provide Orchard with capital and operational support to accelerate product innovation, expand capabilities (including point-of-care testing integrations), and support leadership transition.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.